Portfolio spans high-performance enterprise computing and edge AI, supporting deployment in customers' own IT environments.
TAIPEI, Oct. 9, 2026 /PRNewswire/ -- Senao Networks Inc. today announced the launch of its new x86 enterprise server portfolio, featured on the company's Senao Computing website at www.senaocomputing.com.

The portfolio, which includes the SR810, SR710, SR610, SE210, and SE110, is designed to support a broad range of enterprise computing and AI workloads, including generative AI, AI inference, model fine-tuning, data analytics, visualization, and intelligent edge computing. NVIDIA RTX GPU support is available in selected configurations.
Bringing AI Closer to Enterprise Data
As enterprises accelerate AI adoption, organizations increasingly need computing infrastructure that can address different workload requirements while maintaining greater control over sensitive corporate data.
Senao Networks' scalable x86 platforms allow enterprises to deploy computing resources according to their workload, performance, and deployment requirements.
For organizations that prefer to operate AI applications within their own IT environments, on-premises deployment can provide greater control over enterprise data, infrastructure, security policies, and AI workloads. Meeting data governance and regulatory requirements depends on the deployment, operational controls, and applicable rules.
"Enterprises are looking for practical ways to bring AI closer to their data and business operations," said Dr. Bou Lin, President at Senao Networks Inc. "Our new x86 enterprise server portfolio provides flexible computing building blocks that allow customers to deploy AI according to their own performance, security, and infrastructure requirements—from the data center to the edge."
Computing Platforms for Enterprise AI Workloads
The portfolio addresses different enterprise computing and AI requirements, with GPU acceleration available in selected configurations:
High-Performance Enterprise Compute – SR810 & SR710
Designed for demanding enterprise computing and AI workloads, including generative AI applications, LLM inference, model fine-tuning, data analytics, visualization, and other GPU-accelerated workloads.
Mainstream Enterprise Compute – SR610
Optimized for enterprise AI inference, data analytics, virtualization, and general-purpose enterprise computing applications.
Edge Intelligence – SE210 & SE110
Compact and efficient platforms designed for localized AI inference, intelligent edge applications, real-time processing, and deployments closer to where enterprise data is generated.

From Enterprise Computing to Edge AI
The portfolio expands Senao Networks' enterprise computing offering.
Building on decades of experience in networking, security appliances, system engineering, and global manufacturing, Senao Networks is extending its capabilities into enterprise computing and AI infrastructure.
The company aims to provide customers and technology partners with flexible computing platforms spanning enterprise servers, AI servers, edge servers, network appliances, and AI infrastructure solutions—helping organizations build practical and scalable computing environments from the data center to the edge.
Explore Senao Computing
The Senao Computing website brings together the company's computing platforms, product specifications, AI solutions, and information on its engineering and manufacturing capabilities for customers and partners.
Senao Computing
https://www.senaocomputing.com
Product Information and Inquiries
For detailed product information, technical specifications, or business inquiries, please visit Senao Computing at www.senaocomputing.com.
About Senao Networks Inc.
Senao Networks Inc. is a provider of networking, security, computing, and AI infrastructure solutions. With extensive capabilities in system design, hardware engineering, software integration, manufacturing, and global supply-chain management, Senao Networks delivers infrastructure platforms for enterprises and technology partners worldwide.
As AI continues to reshape enterprise infrastructure, Senao Networks is expanding its capabilities from networking and security into enterprise computing, AI servers, and intelligent edge platforms—supporting customers as they build the infrastructure required for the AI era.
Media Contact
Contact Name: Jean Chen
Title: Product Marketing
Company: Senao Networks Inc.
Email: jean.chen@senao.com
Phone: +886-3-3289289 #6188
Intel, the Intel logo, and Xeon are trademarks of Intel Corporation or its subsidiaries. NVIDIA and RTX are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. All other trademarks are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/senao-networks-launches-x86-enterprise-server-series-for-enterprise-ai-302902674.html
Roche versucht nach einer Phase von Forschungsrückschlägen und Belastungen durch auslaufende Patente, das Tempo in der Medikamentenentwicklung deutlich zu erhöhen. Am Pharma-Investorentag unterstrich die Pharmasparte des Basler Konzerns den Anspruch, in Forschung und Entwicklung weiter zur Spitzengruppe zu gehören. Zentral sind dabei ein strengeres Management der Pipeline, Effizienzprogramme und der verstärkte Einsatz künstlicher Intelligenz entlang der Wertschöpfungskette.
Pharma-Chefin Teresa Graham verwies auf eine sichtbar verbesserte Bilanz seit dem letzten „Pharma Day“: In zehn zulassungsrelevanten Studien habe Roche die gesetzten Ziele erreicht, sechs Programme seien in die zulassungsrelevende Phase vorgerückt, drei weitere in Phase II. Insgesamt verfügt Roche nach eigenen Angaben über bis zu 20 neue Wirkstoffe, die bis 2030 auf den Markt kommen könnten. Einzelne Kandidaten wie das Brustkrebsmittel Giredestrant traut der Konzern dabei jeweils Spitzenumsätze im zweistelligen Milliardenbereich zu.
Um diese Ambitionen abzusichern, verschärft Roche die internen Selektionskriterien. Ende 2023 führte der Konzern mit „The Bar“ einen neuen Bewertungsrahmen für die Pipeline ein. Nur Wirkstoffkandidaten, die klar definierte Anforderungen erfüllen, werden weiterentwickelt. Medizinchef Levi Garraway bezeichnete „The Bar“ als Leitbild für Forschung und Entwicklung. Die Auswahl potenzieller Projekte sei damit spürbar strenger geworden – mit dem Ziel, Ressourcen konsequent auf die Erfolg versprechendsten Programme zu konzentrieren und die Erfolgsquote in späten Studienphasen zu stabilisieren oder weiter zu erhöhen.
Parallel dazu treibt Roche ein Effizienzprogramm voran, um Mittel aus weniger renditestarken in wachstumsstärkere Projekte umzuschichten. Die Entwicklung neuer Medikamente soll deutlich beschleunigt werden, was insbesondere in umkämpften Indikationen wie Onkologie sowie in wachstumsstarken Bereichen wie Herz-Kreislauf- und Stoffwechselerkrankungen an Bedeutung gewinnt. Damit will Roche erwartete Umsatzeinbussen durch Patentabläufe mehr als kompensieren und sich bis zum Ende des Jahrzehnts ein Portfolio aufbauen, das von mehreren potenziellen Blockbustern getragen wird.